Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces 18F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosis. Issue 3 (23rd February 2021)

• Record Type: Journal Article
• Authors: Buschner, Gabriel; Feuerecker, Benedikt; Spinner, Sabine; Seidl, Christof; Essler, Markus
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 3(2021)
• Page Start: 630
• Page End: 639
• Publication Date: 2021-02-23
• Subjects: Cancer metabolism -- acute myeloid leukemia -- apoptosis -- ABT-737 -- all trans retinoic acid (ATRA) -- 18F-FDG; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1839648
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Acute myeloid leukemia (AML) is a malignant disease of the bone marrow, comprising various subtypes. We have investigated seven different AML cell lines that showed different sensitivities toward the inducer of apoptosis ABT-737, with IC50 concentrations ranging from 9.9 nM to 1.8 µM. Besides, the AML cell lines revealed distinct differences in 18 F-FDG uptake ranging from 4.1 to 11.0%. Moreover, the Pearson coefficient (0.363) suggests a moderate correlation between 18 F-FDG uptake and the IC50 values of ABT-737. Differentiation of the AML cell lines NB-4 and AML-193 with all-trans-retinoic-acid (ATRA) induced a significant increase in sensitivity towards ABT-737 along with a reduced uptake of 18 F-FDG. Therefore, 18 F-FDG uptake could be predictive on sensitivity to treatment with ABT-737. Furthermore, because differentiation treatment of AML cells using ATRA reduced 18 F-FDG uptake and increased sensitivity towards ABT-737, a combined treatment regimen with ATRA and ABT-737 might be a promising therapeutic option in the future.